Overcome Targeted Alpha Therapy Challenges for Clinical Translation

Targeted alpha therapies are emerging as a promising area of radiopharmaceutical development, delivering high-potency, short-range radiation designed to target cancer cells while limiting damage to surrounding healthy tissue. As pipelines expand beyond beta-emitting therapies, radionuclides including
actinium-225 (Ac-225)
,
lead-212 (Pb-212)
and
astatine-211 (At-211)
are attracting growing interest. This webinar explores the scientific and technical considerations shaping the development and clinical translation of targeted alpha therapy.
Despite their therapeutic potential, advancing targeted alpha therapies toward clinical applications requires overcoming several scientific and technical challenges that can influence overall development success. Key considerations include vector selection, radiochemistry, chelation and stability, as well as the complexities of dosimetry, biodistribution and toxicity. Additionally, daughter radionuclide redistribution, isotope availability and production scalability introduce further challenges that can affect therapeutic safety, efficacy and clinical readiness.
The featured speaker will explore the evolving targeted alpha therapy landscape, from key radionuclides and radiochemistry strategies to dosimetry, toxicity, isotope supply and translation. Attendees will gain a practical perspective on the scientific challenges that must be addressed to advance alpha-emitting radiopharmaceuticals toward the clinic.
Register for this webinar to learn about the key challenges in targeted alpha therapy development and the considerations necessary to support successful clinical translation.

Who Should Attend
This webinar will appeal to:
Radiopharmaceutical and RLT Developers
R&D and Translational Scientists
Radiochemists and Medicinal Chemists
Preclinical and
In Vivo
Researchers
Imaging and Nuclear Medicine Scientists
Dosimetry and Medical Physics Specialists
Oncology and Clinical Development teams

What You Will Learn
Attendees will gain insight into:
How alpha therapies differ from beta-emitting approaches
Key considerations for
Ac-225, Pb-212
and
At-211
Radiochemistry, chelation and stability challenges
Dosimetry, biodistribution and clinical translation
Daughter redistribution and toxicity considerations
Production, supply and scalability challenges

Register free on Xtalks:
https://xtalks.com/webinars/overcome-targeted-alpha-therapy-challenges-for-clinical-translation/